Business Context and Reporting Period
This Form 8-K is filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on February 16, 2022. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the continued listing of the Company's common stock (Trading Symbol: CBIO).
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the stock price compliance issue.
Material Changes
- Stock Price Deficiency: The Company's common stock closing bid price fell below $1.00 for 30 consecutive trading days.
- Regulatory Status: The Company is currently non-compliant with Nasdaq Marketplace Rule 5550(a)(2) (Minimum Bid Price Requirement).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days (until August 15, 2022) to regain compliance.
- Resolution Criteria: Compliance is achieved if the closing bid price is at or above $1.00 per share for a minimum of 10 consecutive trading days before the deadline.
- Extension Possibility: If compliance is not met by August 15, 2022, Nasdaq may grant a second 180-day grace period, provided the Company meets other listing standards and notifies Nasdaq of its intent to cure.
- Delisting Risk: Failure to regain compliance within the allotted periods may result in delisting. The Company retains the right to appeal a delisting determination.
- Management Action: Management intends to actively monitor the stock price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of CBIO to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price for 10 consecutive trading days above $1.00 to confirm compliance.
- Review future filings for announcements regarding a potential reverse stock split or other capital structure changes intended to raise the share price.
- Check for any subsequent 8-K filings regarding the expiration of the compliance period or the granting of an extension.